PDF(Pubmed)
Abstract：
BACKGROUND: The prevention and control of dyslipidemia, as an important risk factor for cardiovascular diseases (CVDs), is a priority for the healthcare system to reduce the burden of these diseases. The purpose of this protocol is to outline the key steps of the first Iranian Dyslipidemia Clinical Practice Guideline development, which can be used by other researchers as a guide to design a standard, comprehensive, evidence-based, and local context-based guideline.
METHODS: This guideline will be developed and reported according to the format of the World Health Organization (WHO) Handbook for Guideline Development. All members of the guideline development team will sign the declaration-of-competing-interests (DOI) forms. The development of the authors\' guideline will be supported by five groups: the steering committee (SC), the Guideline Developing Group (GDG), the systematic review (evidence synthesis) group, and the external review group. The authors will also establish a patient advisory group to inform guideline development by patients\' values and preferences. The SC and GDG will determine the scope of the guideline and will design PICO questions. The systematic review group will systematically search Embase, PubMed, Scopus, Web of Sciences, Cochrane Library, and Google Scholar from inception. The systematic review group will assess the risk of bias and create evidence summaries using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system. The recommendations of this guideline will be divided into strong recommendations and weak or conditional recommendations or suggestions.
CONCLUSIONS: This clinical practice guideline will provide clinicians and healthcare professionals with new evidence-based recommendations for the diagnosis, management, and treatment of dyslipidemia in children and adults.
METHODS: This guideline will be developed and reported according to the format of the World Health Organization (WHO) Handbook for Guideline Development. All members of the guideline development team will sign the declaration-of-competing-interests (DOI) forms. The development of the authors\' guideline will be supported by five groups: the steering committee (SC), the Guideline Developing Group (GDG), the systematic review (evidence synthesis) group, and the external review group. The authors will also establish a patient advisory group to inform guideline development by patients\' values and preferences. The SC and GDG will determine the scope of the guideline and will design PICO questions. The systematic review group will systematically search Embase, PubMed, Scopus, Web of Sciences, Cochrane Library, and Google Scholar from inception. The systematic review group will assess the risk of bias and create evidence summaries using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system. The recommendations of this guideline will be divided into strong recommendations and weak or conditional recommendations or suggestions.
CONCLUSIONS: This clinical practice guideline will provide clinicians and healthcare professionals with new evidence-based recommendations for the diagnosis, management, and treatment of dyslipidemia in children and adults.
摘要：
背景：预防和控制血脂异常，作为心血管疾病（CVD）的重要危险因素，是医疗保健系统减轻这些疾病负担的优先事项。该协议的目的是概述第一个伊朗血脂异常临床实践指南开发的关键步骤，它可以被其他研究人员用作设计标准的指南，全面,以证据为基础,和基于本地上下文的指南。
方法：本指南将根据世界卫生组织（WHO）指南制定手册的格式制定和报告。指南开发团队的所有成员将签署竞争利益声明（DOI）表格。作者指南的制定将得到五个小组的支持：指导委员会（SC），指导方针发展小组(GDG)，系统审查(证据综合)小组，和外部审查小组。作者还将建立一个患者咨询小组，以根据患者的价值观和偏好制定指南。SC和GDG将确定指南的范围，并设计PICO问题。系统审查小组将系统地搜索Embase，PubMed,Scopus,WebofSciences,科克伦图书馆,和谷歌学者从一开始。系统审查小组将评估偏见的风险，并使用建议评估的分级创建证据摘要。发展,和评估（等级）系统。本指南的建议将分为强建议和弱或有条件的建议或建议。
结论：本临床实践指南将为临床医生和医疗保健专业人员提供新的循证诊断建议，管理,以及儿童和成人血脂异常的治疗。
方法：本指南将根据世界卫生组织（WHO）指南制定手册的格式制定和报告。指南开发团队的所有成员将签署竞争利益声明（DOI）表格。作者指南的制定将得到五个小组的支持：指导委员会（SC），指导方针发展小组(GDG)，系统审查(证据综合)小组，和外部审查小组。作者还将建立一个患者咨询小组，以根据患者的价值观和偏好制定指南。SC和GDG将确定指南的范围，并设计PICO问题。系统审查小组将系统地搜索Embase，PubMed,Scopus,WebofSciences,科克伦图书馆,和谷歌学者从一开始。系统审查小组将评估偏见的风险，并使用建议评估的分级创建证据摘要。发展,和评估（等级）系统。本指南的建议将分为强建议和弱或有条件的建议或建议。
结论：本临床实践指南将为临床医生和医疗保健专业人员提供新的循证诊断建议，管理,以及儿童和成人血脂异常的治疗。
